This study aimed to assess ivosidenib cost-effectiveness as a subsequent-line treatment for advanced ICC with IDH1 mutations in comparison with that of mFOLFOX and 5-FU/LV from the Taiwan National Health Insurance Administration (NHIA)’s perspective and propose a reference price for Taiwan NHIA. Here, IDH1 is linked to intrahepatic cholangiocarcinoma.